(BHC) Bausch Health Companies - Ratings and Ratios
Exchange: NYSE •
Country: Canada •
Currency: USD •
Type: Common Stock •
ISIN: CA0717341071
Gastroenterology, Dermatology, Neurology, Ophthalmology, Aesthetics
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 76.8% |
| Value at Risk 5%th | 105% |
| Relative Tail Risk | -16.55% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.04 |
| Alpha | -23.60 |
| CAGR/Max DD | -0.04 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.596 |
| Beta | 0.839 |
| Beta Downside | 1.669 |
| Drawdowns 3y | |
|---|---|
| Max DD | 59.28% |
| Mean DD | 27.08% |
| Median DD | 26.40% |
Description: BHC Bausch Health Companies November 11, 2025
Bausch Health Companies Inc. (NYSE:BHC) is a diversified specialty pharma and medical-device firm headquartered in Laval, Canada. It markets products across gastroenterology, hepatology, neurology, dermatology, generic and OTC medicines, aesthetic devices, and eye-care solutions. The business is organized into five segments: Salix (GI therapies), International (branded, generic, OTC, and aesthetic devices outside North America), Solta Medical (aesthetic devices), Diversified (neurology, dermatology, generics, dentistry), and Bausch + Lomb (vision-care, surgical and ophthalmic pharmaceuticals).
As of FY 2023, BHC generated roughly $2.5 billion in revenue, with an adjusted EBITDA margin near 15 % and net debt of about $5.3 billion, reflecting its capital-intensive acquisition strategy. Key economic drivers include an aging global population that fuels demand for chronic-disease treatments (especially GI and eye-care), continued growth in the OTC self-care market, and pricing pressure from generic competition. The company’s pipeline features several late-stage generic GI products and new ophthalmic formulations, which could improve margin expansion if successfully launched.
For a deeper quantitative assessment, you may find ValueRay’s detailed valuation model for BHC worth reviewing.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (362.0m TTM) > 0 and > 6% of Revenue (6% = 495.6m TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA 0.25pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 17.61% (prev 8.92%; Δ 8.69pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 1.51b > Net Income 362.0m (YES >=105%, WARN >=100%) |
| Net Debt (19.68b) to EBITDA (4.79b) ratio: 4.11 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.30 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (373.1m) change vs 12m ago 1.28% (target <= -2.0% for YES) |
| Gross Margin 81.55% (prev 70.87%; Δ 10.68pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 30.97% (prev 35.70%; Δ -4.72pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.14 (EBITDA TTM 4.79b / Interest Expense TTM 3.13b) >= 6 (WARN >= 3) |
Altman Z'' 0.06
| (A) 0.05 = (Total Current Assets 6.24b - Total Current Liabilities 4.79b) / Total Assets 26.80b |
| (B) -0.36 = Retained Earnings (Balance) -9.55b / Total Assets 26.80b |
| (C) 0.13 = EBIT TTM 3.57b / Avg Total Assets 26.67b |
| (D) -0.03 = Book Value of Equity -839.2m / Total Liabilities 26.44b |
| Total Rating: 0.06 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 52.45
| 1. Piotroski 2.50pt |
| 2. FCF Yield 4.94% |
| 3. FCF Margin 13.14% |
| 4. Debt/Equity -37.24 |
| 5. Debt/Ebitda 4.11 |
| 6. ROIC - WACC (= 6.33)% |
| 7. RoE -38.20% |
| 8. Rev. Trend -11.57% |
| 9. EPS Trend -6.82% |
What is the price of BHC shares?
As of December 02, 2025, the stock is trading at USD 7.05 with a total of 6,397,554 shares traded.
Over the past week, the price has changed by +15.38%, over one month by +3.52%, over three months by -8.20% and over the past year by -9.85%.
Over the past week, the price has changed by +15.38%, over one month by +3.52%, over three months by -8.20% and over the past year by -9.85%.
Is BHC a buy, sell or hold?
Bausch Health Companies has received a consensus analysts rating of 3.00.
Therefor, it is recommend to hold BHC.
- Strong Buy: 0
- Buy: 1
- Hold: 5
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the BHC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 7.2 | 1.7% |
| Analysts Target Price | 7.2 | 1.7% |
| ValueRay Target Price | 6.9 | -2.1% |
BHC Fundamental Data Overview November 26, 2025
Market Cap USD = 2.27b (2.27b USD * 1.0 USD.USD)
P/E Trailing = 6.299
P/E Forward = 1.4233
P/S = 0.226
P/B = 18.7773
P/EG = 0.6315
Beta = 0.397
Revenue TTM = 8.26b USD
EBIT TTM = 3.57b USD
EBITDA TTM = 4.79b USD
Long Term Debt = 20.46b USD (from longTermDebt, last quarter)
Short Term Debt = 578.4m USD (from shortTermDebt, last quarter)
Debt = 21.02b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 19.68b USD (from netDebt column, last quarter)
Enterprise Value = 21.95b USD (2.27b + Debt 21.02b - CCE 1.34b)
Interest Coverage Ratio = 1.14 (Ebit TTM 3.57b / Interest Expense TTM 3.13b)
FCF Yield = 4.94% (FCF TTM 1.08b / Enterprise Value 21.95b)
FCF Margin = 13.14% (FCF TTM 1.08b / Revenue TTM 8.26b)
Net Margin = 4.38% (Net Income TTM 362.0m / Revenue TTM 8.26b)
Gross Margin = 81.55% ((Revenue TTM 8.26b - Cost of Revenue TTM 1.52b) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 69.80%)
Tobins Q-Ratio = 0.82 (Enterprise Value 21.95b / Total Assets 26.80b)
Interest Expense / Debt = 9.52% (Interest Expense 2.00b / Debt 21.02b)
Taxrate = 17.89% (39.0m / 218.0m)
NOPAT = 2.93b (EBIT 3.57b * (1 - 17.89%))
Current Ratio = 1.30 (Total Current Assets 6.24b / Total Current Liabilities 4.79b)
Debt / Equity = -37.24 (negative equity) (Debt 21.02b / totalStockholderEquity, last quarter -564.4m)
Debt / EBITDA = 4.11 (Net Debt 19.68b / EBITDA 4.79b)
Debt / FCF = 18.14 (Net Debt 19.68b / FCF TTM 1.08b)
Total Stockholder Equity = -947.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.35% (Net Income 362.0m / Total Assets 26.80b)
RoE = -38.20% (negative equity) (Net Income TTM 362.0m / Total Stockholder Equity -947.6m)
RoCE = 18.28% (EBIT 3.57b / Capital Employed (Equity -947.6m + L.T.Debt 20.46b))
RoIC = 14.27% (NOPAT 2.93b / Invested Capital 20.53b)
WACC = 7.95% (E(2.27b)/V(23.29b) * Re(9.11%) + D(21.02b)/V(23.29b) * Rd(9.52%) * (1-Tc(0.18)))
Discount Rate = 9.11% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.07%
[DCF Debug] Terminal Value 65.78% ; FCFE base≈1.05b ; Y1≈691.9m ; Y5≈316.4m
Fair Price DCF = 14.15 (DCF Value 5.24b / Shares Outstanding 370.5m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -6.82 | EPS CAGR: -2.51% | SUE: 0.38 | # QB: 0
Revenue Correlation: -11.57 | Revenue CAGR: -20.89% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.77 | Chg30d=-0.037 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=4.16 | Chg30d=-0.098 | Revisions Net=+1 | Growth EPS=+7.0% | Growth Revenue=+3.3%
P/E Trailing = 6.299
P/E Forward = 1.4233
P/S = 0.226
P/B = 18.7773
P/EG = 0.6315
Beta = 0.397
Revenue TTM = 8.26b USD
EBIT TTM = 3.57b USD
EBITDA TTM = 4.79b USD
Long Term Debt = 20.46b USD (from longTermDebt, last quarter)
Short Term Debt = 578.4m USD (from shortTermDebt, last quarter)
Debt = 21.02b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 19.68b USD (from netDebt column, last quarter)
Enterprise Value = 21.95b USD (2.27b + Debt 21.02b - CCE 1.34b)
Interest Coverage Ratio = 1.14 (Ebit TTM 3.57b / Interest Expense TTM 3.13b)
FCF Yield = 4.94% (FCF TTM 1.08b / Enterprise Value 21.95b)
FCF Margin = 13.14% (FCF TTM 1.08b / Revenue TTM 8.26b)
Net Margin = 4.38% (Net Income TTM 362.0m / Revenue TTM 8.26b)
Gross Margin = 81.55% ((Revenue TTM 8.26b - Cost of Revenue TTM 1.52b) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 69.80%)
Tobins Q-Ratio = 0.82 (Enterprise Value 21.95b / Total Assets 26.80b)
Interest Expense / Debt = 9.52% (Interest Expense 2.00b / Debt 21.02b)
Taxrate = 17.89% (39.0m / 218.0m)
NOPAT = 2.93b (EBIT 3.57b * (1 - 17.89%))
Current Ratio = 1.30 (Total Current Assets 6.24b / Total Current Liabilities 4.79b)
Debt / Equity = -37.24 (negative equity) (Debt 21.02b / totalStockholderEquity, last quarter -564.4m)
Debt / EBITDA = 4.11 (Net Debt 19.68b / EBITDA 4.79b)
Debt / FCF = 18.14 (Net Debt 19.68b / FCF TTM 1.08b)
Total Stockholder Equity = -947.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.35% (Net Income 362.0m / Total Assets 26.80b)
RoE = -38.20% (negative equity) (Net Income TTM 362.0m / Total Stockholder Equity -947.6m)
RoCE = 18.28% (EBIT 3.57b / Capital Employed (Equity -947.6m + L.T.Debt 20.46b))
RoIC = 14.27% (NOPAT 2.93b / Invested Capital 20.53b)
WACC = 7.95% (E(2.27b)/V(23.29b) * Re(9.11%) + D(21.02b)/V(23.29b) * Rd(9.52%) * (1-Tc(0.18)))
Discount Rate = 9.11% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.07%
[DCF Debug] Terminal Value 65.78% ; FCFE base≈1.05b ; Y1≈691.9m ; Y5≈316.4m
Fair Price DCF = 14.15 (DCF Value 5.24b / Shares Outstanding 370.5m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -6.82 | EPS CAGR: -2.51% | SUE: 0.38 | # QB: 0
Revenue Correlation: -11.57 | Revenue CAGR: -20.89% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.77 | Chg30d=-0.037 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=4.16 | Chg30d=-0.098 | Revisions Net=+1 | Growth EPS=+7.0% | Growth Revenue=+3.3%
Additional Sources for BHC Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle